Quantcast
Last updated on April 24, 2014 at 6:40 EDT

Latest Angiotech Pharmaceuticals Inc. Stories

2014-03-21 12:24:30

VANCOUVER, March 21, 2014 /PRNewswire/ - Angiotech Pharmaceuticals, Inc. ("ANPI") today announced its financial results for the quarter and year ended December 31, 2013 as well as number of recent developments. "We are pleased to have concluded 2013 by recording yet another year of improved business results as compared to the past several years," said Tammy Neske, Chief Business Officer of Angiotech. "2013 was a year of exceptional achievement, beginning with the successful sale...

2013-10-11 08:24:20

VANCOUVER, Oct. 11, 2013 /PRNewswire/ - Angiotech Pharmaceuticals, Inc. ("Angiotech") announced today that its shareholders and Board of Directors have approved changes to the Company's executive management team and Board of Directors. Effective October 8, Thomas Bailey and Angiotech mutually agreed that Mr. Bailey would transition from his current role as President and CEO of Angiotech, and into a Board role. As of that same date, at the Company's Annual General Meeting, Mr....

2013-07-25 12:28:08

Private Call and Webcast Available Only to Shareholders of Record VANCOUVER, July 25, 2013 /PRNewswire/ - Angiotech Pharmaceuticals, Inc. will host a conference call and webcast to review its results for the second quarter ended June 30, 2013 on Thursday, August 8, 2013 at 1:00 PM ET (10:00 AM PT).  The call and webcast will be available only to existing holders of Angiotech common stock, and only current shareholders of record will be eligible to receive financial and certain...

2013-05-31 08:24:46

VANCOUVER, May 31, 2013 /PRNewswire/ - Angiotech Pharmaceuticals, Inc. ("Angiotech") announced today that a return of capital will be provided to all holders of record, as at May 31, 2013, of its common shares, and to employees holding restricted share units, in the amount of $6 in cash per common share, or per restricted share unit. The amount to be distributed reflects a substantial portion of the remaining net proceeds received to date per Angiotech's recently completed sale, as...

2013-04-15 08:29:07

VANCOUVER, April 15, 2013 /PRNewswire/ - Angiotech Pharmaceuticals, Inc. ("Angiotech") announced that on April 12, 2013, Deutsche Bank National Trust Company (the "FRN Trustee"), issued a notice of redemption on behalf of Angiotech under the indenture to redeem $44,024,000 in aggregate principal amount of Angiotech's Senior Secured Floating Rate Notes due 2013 (the "FR Notes", CUSIP Number 034918AH5), which are all of the FR Notes that will remain outstanding following the previously...

2013-04-15 08:28:58

VANCOUVER, April 15, 2013 /PRNewswire/ - Angiotech Pharmaceuticals, Inc. ("Angiotech") announced today that on April 12, 2013 it completed its transaction, as previously announced on March 25, 2013, to sell certain of its subsidiaries, comprising Angiotech's Interventional Products Business, to Argon Medical Devices, Inc. ("Argon"), a portfolio company of RoundTable Healthcare Partners, and certain of its affiliates.  Angiotech received shareholder approval to conclude the...

2013-03-25 12:26:55

LAKE FOREST, Ill., March 25, 2013 /PRNewswire/ -- RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that its portfolio company, Argon Medical Devices, Inc. ("Argon" or the "Company"), entered into a definitive agreement to acquire the Interventional Products Business of Angiotech Pharmaceuticals, Inc. ("Angiotech"). The Interventional Products Business manufactures and markets disposable...

2013-03-25 08:27:05

VANCOUVER, March 25, 2013 /PRNewswire/ - Angiotech Pharmaceuticals, Inc. ("Angiotech") announced today that it had entered into a definitive agreement to sell certain of its subsidiaries, comprising Angiotech's Interventional Products Business, to Argon Medical Devices, Inc. ("Argon"), a portfolio company of RoundTable Healthcare Partners, for $362.5 million in cash consideration. Angiotech expects the transaction will close prior to the end of April 2013. "This important...

2013-03-18 16:25:03

VANCOUVER, March 18, 2013 /PRNewswire/ - Angiotech Pharmaceuticals, Inc. will host a conference call discussing its financial results for the fourth quarter and year ended December 31, 2012, on Tuesday, April 2, 2013 at 10:00 am PT (1:00 pm ET). Dial-in information for the earnings call on April 2, 2013 is as follows: North America (toll-free): (877) 299-4454 International:  (617) 597-5447 Enter Passcode:  11331267 A live webcast of the earnings call will be available to...

2012-11-16 20:21:22

VANCOUVER, Nov. 16, 2012 /PRNewswire/ - Angiotech Pharmaceuticals, Inc. ("Angiotech") announced that its partner Cook Medical, Inc. ("Cook") received approval on November 15, 2012 from the U.S. Food and Drug Administration ("FDA") to market and sell the proprietary Zilver® PTX® drug-eluting peripheral stent, adding the United States to the list of over 50 markets, including the European Union and Japan, where Zilver PTX is approved for sale. Zilver PTX is the first...